# 1. Financial Performance ## A. Key Figures * Revenue (Q3 FY'26): ₹8.5B (+10.9%) · Formulations: ₹4.8B (+20%) · API: ₹3.6B (+2.9%) * 9M Revenue (FY'26): ₹2,500 Cr (+11.9%) · Formulations: ₹1,360 Cr (+14.5%) · API: ₹1,100 Cr (+9.6%) * **Adjusted EBITDA (9M FY'26):** **₹500 Cr** (+58%) · **Margin: >20%** * **Adjusted EBITDA (Q3 FY'26):** **₹185 Cr** · **Margin: 21%** (+390 bps YoY) * PAT (9M FY'26): ₹1.5 Bn (>3x YoY) · PBT: ₹2.2 Bn (3.5x YoY) ## B. Revenue Growth * **First Unified Quarter:** Q3 FY'26 marks the inaugural results for the merged SeQuent-Viyash entity, reflecting integrated operations and a unified growth platform. * **Strong Segment Momentum:** Formulations delivered robust double-digit growth, while API achieved a sustainable quarterly run rate of **₹100 Cr**, with further growth expected in FY'27. * **Revenue Trajectory:** 9-month revenue growth outpaced Q3, indicating accelerating top-line momentum across geographies and business lines. ## C. Profitability Trends * **Margin Expansion Accelerates:** EBITDA margin improved 390 bps YoY in Q3, driven by operational efficiency, favorable mix, and synergy realization despite one-time merger costs. * **One-Time Charges Identified:** **₹41 Cr** in merger-related expenses (stamp duty, advisory fees) and **₹7 Cr** MAT credit reversal were confirmed as non-recurring, clearing path for normalized earnings. * **Profitability Leverage:** Despite onetime costs, PBT and PAT grew substantially YoY, with gross margin expanding over **300 bps** due to improved efficiency and product mix. * **Sustainable Cost Discipline:** ESOP expenses are declining under the old scheme; new ESOP to be phased over **1–2 years**, ensuring controlled near-term dilution. ## D. Balance Sheet Strength * **Strategic Financial Positioning:** Balance sheet now acts as a growth enabler, with low debt (**₹200+ Cr**) and strong cash flow generation supporting both organic investment and M&A optionality. * **Capital Allocation Clarity:** Focus over next 12 months on synergy capture, integration discipline, and targeted investments—especially in **companion animal health**—to enhance returns. ## E. Cash Flow Outlook * **Robust FCF Forecast:** Company expects strong free cash flow in FY'27, driven by **₹800 Cr EBITDA** and low capex, enabling accelerated deleveraging. * **Debt Reduction Underway:** High-cost debt is being repaid early, with meaningful reduction in interest burden anticipated in coming quarters. --- # 2. Product & Segment Performance ## A. Key Figures * **Revenue Mix:** **55% formulations** · **45% API** (targeted stable over 3–5 years) * **SeQuent API Business:** Crossed **₹400 Cr** for the first time since 2022 * **CDMO Revenue:** **₹70–90 Cr** estimated for current year; **₹70–80 Cr** generated from complex products in last 12–18 months * **Animal Health API Growth:** First significant increase in **4–5 years**, with rapid growth expected next year * **Companion Animal Genericization:** Current penetration at **15%–16%**, vs. 85–90% in human health ## B. API & Formulations Strategy * **Core API Strength Maintained:** API remains foundational, with rapid development, high efficiency, and **45% backward integration** achieved in key products. * **Strategic Repositioning in US:** Mature products being shifted to India; focus now on **complex, differentiated products** and sustainable growth via recent commercialization. * **Formulations Strategy Optimized:** Leverages India’s low-cost base for high-volume mature products, while reserving capacity for **complex new launches** and government opportunities. * **Albendazole Drives Momentum:** Significant volume growth in Albendazole contributing to strong performance, supported by integrated Viyash-SeQuent efforts. ## C. Animal Health Growth Trajectory * **Companion Animals = Top Strategic Priority:** Designated as key focus for FY'27, backed by large US pet populations and **massive genericization runway** ahead. * **Market Leadership Aspiration:** Targeting top 10 position among animal generics, with **60% of portfolio** already dedicated to companion animals. * **Growth Engine Building:** Expanding R&D and manufacturing in India, evaluating M&A and partnerships, while growing field force to **200** for farm animal outreach. * **API Reacceleration Underway:** After years of stagnation, Animal Health API growth has resumed and is poised for acceleration due to infrastructure and client credibility gains. ## D. CDMO Momentum & Differentiation * **CDMO Gaining Traction:** Now a material business segment with **robust RFQ inflow**, serving both human and animal health innovators, including 80% of animal health revenue from innovators. * **Differentiated by Speed and Quality:** Competitive edge lies in **faster execution**, **cytotoxic capabilities**, and **proven EHS/sustainability standards** validated by global clients. * **Onco Facility a Key Asset:** One of few high-quality Indian facilities of its kind, driving **₹70–80 Cr in complex product revenue** and preferred-partner status. * **Near-Term Revenue Visibility:** CDMO revenues at **reasonable level** with continuous growth expected, though major scale-up anticipated in **2–3 years**. --- # 3. Geography & Market Mix ## A. Key Figures *No significant quantitative financial metrics available for extraction.* ## A. Europe Expansion * **Accelerated European Commercialization:** Expansion driven by strengthened direct field forces in Spain, Benelux, and Sweden, supported by new distribution agreements and relaunched companion animal initiatives. * **Regulatory-Enabled Scale-Up:** EU approval of manufacturing sites in Spain and Turkey has unlocked broader product commercialization across Europe. * **Strategic Portfolio Leverage:** Existing farm animal approvals and a robust product portfolio are enabling market expansion into Italy, Germany, France, and the UK, with field force build-outs underway in key geographies. ## B. Brazil & LatAm Strength * **LatAm Growth Platform:** Brazil demonstrates consistent performance and serves as a regional hub for expansion into Mexico and neighboring markets. * **Third-Party Distribution as Growth Lever:** New partnerships with innovator and specialty companies, including distribution of products from Zoetis and Boehringer Ingelheim, enhance revenue streams and competitive positioning. * **Global Reach via GMP Hubs:** Turkey and Brazil’s GMP-approved facilities enable supply to regulated markets and support scaling of injectable animal health products, aligned with veterinarian-driven demand trends. ## C. India & Emerging Markets * **Strategic Pivot from Low-End Markets:** Shift in focus from India, Bangladesh, and Pakistan toward developed and high-growth emerging markets, complemented by a successful CDMO business launch. * **High-Profile India Market Entry:** Exclusive distribution deal with Boehringer Ingelheim—ranked #3 globally—marks a strategic foothold in India’s companion animal segment, with commercialization live as of February. * **Targeted Expansion in High-Potential Regions:** Five-year plan emphasizes entry and growth in farm animal markets across Southeast Asia and Africa, while M&A remains secondary to organic investment. --- # 4. Manufacturing & Capacity ## A. Key Figures * **Annual Cost Savings (Mangalore Divestment):** **$1 Mn** expected * **Synergy Target:** **₹50–60 Cr** over 12–18 months * **Site Shutdown Savings:** **₹7 Cr** from analytical site closure ## B. Site Integration * **Network Optimization Underway:** Strategic shutdowns and facility rationalization driving cost savings, with integration 3 months into plan and on track to deliver **₹50–60 Cr** synergies. * **Regulatory Progress:** New Albendazole line at Viyash site validated and filed, enabling segregation of Human and Animal Health production for improved compliance and scalability. * **Merger Synergies Phased:** Full benefits expected over 18–24 months; R&D synergies to materialize over 3–4 years, while near-term gains stem from network and operational streamlining. * **Corporate Integration Complete:** Shared services and corporate functions now fully unified, supporting seamless cross-site operations. ## C. Backward Integration * **Margin Expansion via Integration:** Fully backward-integrated, FDA-approved sites have enabled significant margin improvement through internalization of key products. * **Enhanced Supply Control:** Six intermediates now produced in-house, boosting capacity utilization and reducing external supply chain dependency. ## D. CDMO Facility Utilization * **CDMO Growth Strategy:** Expansion pursued via internal scale-up and potential M&A, leveraging unified R&D platform and innovation engine to capture external manufacturing demand. --- # 5. R&D & Product Launches ## A. New Product Pipeline * **Integrated R&D Driving Innovation:** Full unification of R&D across Animal and Human Health has enabled the development and validation of **4 new Animal Health products** in the past year, enhancing portfolio value. * **Strategic Shift to High-Value CDMO:** Company is positioning for entry into NCE and patent-protected CDMO spaces within **2–3 years**, marking a shift toward higher-margin, differentiated offerings. * **Growth Trajectory from Differentiation:** Strong R&D foundation expected to fuel launch of differentiated animal health products, underpinning substantial growth over the next **3–4 years**. * **Pipeline Execution:** Ongoing new product launches with market acceptance mitigate regulatory risk and support sustained commercial momentum. ## B. Lifecycle Management * **Near-Term Revenue Catalysts:** Multiple CDMO lifecycle management projects completed validation and are set for commercialization next year, contributing to revenue growth. * **Market Tailwinds from Patent Expirations:** Strategic focus on supporting innovators aligns with wave of blockbuster patent expirations over the next **3 years**, driving demand for outsourced, scalable manufacturing. * **Growth Opportunity in Complex Generics:** Lifecycle management offers significant potential over **2–3 years**, especially in Europe, where specialty firms seek partners with scale and technical expertise. ## C. First-to-File Advantage * **Competitive Edge via Exclusivity:** Majority of new launches are first-to-file, securing **10%–20% market exclusivity** and high-margin returns. * **Customer Stickiness Through Integration:** Clients locked in via tech transfer, contract manufacturing, and process optimization, creating high barriers to competitor substitution. --- # 6. Risks & Regulatory Factors ## A. Key Figures * **One-Time Tax Impact:** **INR 48–49 Cr** total (including **INR 7 Cr** additional) * **Regulatory Timelines:** Approvals expected in **4–18 months** for cost initiatives · **18–24 months** for new products * **Site Approval Acceleration:** Vendor closures in **4 months** vs. typical **2–3 years** ## B. Tax Policy Changes * **Elevated One-Time Costs:** Transition to new tax regime resulted in significant one-time expenses, though MAT credit refund potential could deliver a **positive near-term impact** if policy shifts favorably. ## C. Approval Timelines * **Regulatory Momentum:** Europe approval secured in **30 days**, enabling faster commercialization in linked markets and demonstrating **best-in-class regulatory execution**. * **Accelerated Site Development:** Site approvals achieved in **four months**—dramatically faster than industry norms—driven by **EHS excellence** and operational agility. ## D. Supply Chain Delays * **Limited Domestic Disruption:** 2022 Indian restrictions on certain veterinary products had **minimal business impact** due to small exposure in affected categories. * **Strategic Market Entry:** International expansion hinges on supply chain and portfolio strength, with **M&A viewed as a viable acceleration lever**. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Guidance:** **₹4,000 Cr** by FY28 (potentially by FY27) * **EBITDA Margin Target:** **20%** (achieved earlier than planned) * **Recent Quarterly Revenue Run Rate:** **₹185 Cr** (latest qtr) · **₹187 Cr** (prior qtr) * **Trailing Revenue:** **~₹900 Cr** (up from ₹860+ Cr) * **EBITDA CAGR Target:** **15–20%** over next 5 years ## B. Revenue & Capital Strategy * **Confident Trajectory:** Management reaffirmed long-term targets, citing current run rate and **near-term visibility into 15% revenue growth**, supporting potential acceleration into FY27. * **Strategic Flexibility at Scale:** At target revenue and **₹800 Cr EBITDA**, company expects capacity for **debt-financed or share-based acquisitions** to enhance long-term value. * **Self-Funded Expansion:** Growth to be financed via internal cash flows, **remaining 25% warrant proceeds (within 12 months)**, and organic generation. ## C. Margin & Business Model Outlook * **Sustainable Margins:** 20% EBITDA margin deemed durable due to balanced segment performance and operational improvements, achieved ahead of original timeline. * **CDMO Acceleration Expected:** CDMO segment poised for **significant growth over 3–4 years**, with full commercialization typically occurring by **Year 4** of project initiation. ## D. Growth Phasing & Strategic Vision * **Phased Geographic Rollout:** Near-to-midterm focus on **emerging markets and Europe**; **North America entry deferred to later phase**. * **Multi-Pillar Growth Engine:** Expansion to be driven by **companion animal health**, **CDMO scale-up**, **post-merger integration**, and **targeted acquisitions**. * **Two-Phase Strategic Execution:** **Phase 1** emphasizes execution; **Phase 2** targets **long-term synergies** for sustained topline and bottomline expansion.